SEC Form 10-K filed by Agenus Inc.

First oral presentation of BOT/BAL neoadjuvant results from the NEOASIS trial in MSI-H and MSS solid tumors New data from the treatment-refractory hepatocellular carcinoma (HCC) cohort of the BOT/BAL Phase 1 trial to be presented Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25–30, 2025 in Chicago, Illinois. The presentations continue to build momentum for Agenus' neoadjuvant immunotherapy program with botensilimab and balstilimab (BOT/BAL), including an oral presentation of the initial results from the NEOASIS trial in solid tumors and a poster

Patients and Healthcare Providers Alike Call for More Innovative, Less Toxic Treatment Options CRC Diagnoses Rise While Current Standards Fall Short Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today announced the results of its national Colorectal Cancer in Focus survey, highlighting critical unmet needs and patient priorities in colorectal cancer (CRC) care. Colorectal cancer remains the second leading cause of cancer-related deaths worldwide and places an enormous burden on individuals, their families and loved ones, and the healthcare system alike.1 The Colorectal Cancer in Focus survey, conducted online in the U.S. from

Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

William Blair downgraded Agenus from Outperform to Mkt Perform

H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

4 - AGENUS INC (0001098972) (Issuer)

10-K - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

8-K - AGENUS INC (0001098972) (Filer)

Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 11th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/886193189.

Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company focused on innovation, today provided a corporate update and reported financial results for the third quarter of 2024. "BOT/BAL represents one of the most significant advancements in cancer immunotherapy, showing remarkable results in MSS colorectal cancer where previous treatments have fallen short," said Garo Armen, Ph.D., Chairman and CEO of Agenus. "Its potential extends beyond this challenging cancer type, with promising efficacy seen in the neoadjuvant setting and other hard-to-treat cancers. While we are excited by

SC 13G/A - AGENUS INC (0001098972) (Subject)

SC 13G/A - AGENUS INC (0001098972) (Subject)

SC 13G/A - AGENUS INC (0001098972) (Subject)